← Back to Clinical Trials
Recruiting NCT07009223

NCT07009223 Lifestyle Interventions to Prevent Cognitive Deficits in Subjects With Depressive Symptoms: From Mechanisms to Clinical Practice

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07009223
Status Recruiting
Phase
Sponsor IRCCS Centro San Giovanni di Dio Fatebenefratelli
Condition Major Depressive Disorder (MDD)
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2025-10-01
Primary Completion 2026-08

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Mediterranean DietPhysical ActivityCognitive Training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 120 participants in total. It began in 2025-10-01 with a primary completion date of 2026-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical study is to investigate if lifestyle changes can help prevent cognitive decline and reduce depressive symptoms in people between the ages of 50 and 80 with depressive symptoms or a diagnosis of major depression, but without signs of cognitive decline. The main questions it aims to answer are: * Does regular physical activity improve mood and memory in people who are depressed or have depressive symptoms? * Does cognitive training help prevent mental difficulties in people at risk of cognitive decline? * Do changes in diet and lifestyle alter the composition of the gut microbiota and immuno-related infiammatory factors? Researchers will compare three different treatment groups to see which intervention is most effective in improving mental and cognitive health. The participants: * Will take part to online sessions on healthy eating based on the Mediterranean diet * Some will do regular exercise, supervised by a personal trainer * Others will do weekly cognitive training in small groups at the hospital * They will provide blood and fecal samples and complete cognitive tests and clinical questionnaires at the beginning, at the end of the treatment (12 weeks), and after 3 months.

Eligibility Criteria

Inclusion Criteria: * Aged between 50 and 80 years; * Diagnosis of DDM according to DSM-5 or depressive symptoms (PHQ-9 or GDS-15 ≥ 5, the choice of test will be justified by the participant's age); * Ability to provide written informed consent. Exclusion Criteria: * Active gastrointestinal disorders; * Autoimmune disorders; * Chronic inflammatory disorders; * Diagnosis of dementia; cognitive impairment or mild functional impairment. * Use of antibiotics and/or anti-inflammatory drugs in the 8 weeks prior to the screening visit.

Contact & Investigator

Central Contact

Elisa Mombelli

✉ emombelli@fatebenefratelli.eu

📞 (+39) 030 35 01 598

Frequently Asked Questions

Who can join the NCT07009223 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying Major Depressive Disorder (MDD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07009223 currently recruiting?

Yes, NCT07009223 is actively recruiting participants. Contact the research team at emombelli@fatebenefratelli.eu for enrollment information.

Where is the NCT07009223 trial being conducted?

This trial is being conducted at Brescia, Italy.

Who is sponsoring the NCT07009223 clinical trial?

NCT07009223 is sponsored by IRCCS Centro San Giovanni di Dio Fatebenefratelli. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology